Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse

MLA

Evalyn E. A. P. Mulder, et al. “Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.” Cancers, vol. 14, no. 12, June 2022. EBSCOhost, https://doi.org/10.3390/cancers14122854.

APA

Evalyn E. A. P. Mulder, Iva Johansson, Dirk J. Grünhagen, Dennie Tempel, Barbara Rentroia-Pacheco, Jvalini T. Dwarkasing, Daniëlle Verver, Antien L. Mooyaart, Astrid A. M. van der Veldt, Marlies Wakkee, Tamar E. C. Nijsten, Cornelis Verhoef, Jan Mattsson, Lars Ny, Loes M. Hollestein, & Roger Olofsson Bagge. (2022). Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse. Cancers, 14(12). https://doi.org/10.3390/cancers14122854

Chicago

Evalyn E. A. P. Mulder, Iva Johansson, Dirk J. Grünhagen, Dennie Tempel, Barbara Rentroia-Pacheco, Jvalini T. Dwarkasing, Daniëlle Verver, et al. 2022. “Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I-II Melanoma Patients at Risk of Disease Relapse.” Cancers 14 (12). doi:10.3390/cancers14122854.